Update: Treatment of systemic lupus erythematosus
نویسندگان
چکیده
منابع مشابه
Neurobrucellosis in systemic lupus erythematosus
Background: Brucellosis is a zoonotic infection which is endemic in many countries. It is a multisystem disease which may present with a broad spectrum of clinical manifestations and complications. Neurobrucellosis is an uncommon complication of brucellosis. Case presentation: A 25-year-old woman with a history of lupus for 5 months referred to the emergency ward of Shahid Beheshti Hosp...
متن کاملTreatment of systemic lupus erythematosus: a 2012 update.
This 2013 update on the treatment of systemic lupus erythrematosus provides rationale for universal use of antimalarials even absent skin or joint manifestations, but chiefly focuses on the management options for refractory cutaneous, articular, and renal disease and current status of biologics; both FDA approved belimumab and off-label infliximab, rituximab, abatacept, and tociluzimab. A discu...
متن کاملA Case of Systemic Lupus Erythematosus
SUMMARY During the course of systemic lupus erythematosus in a 10 year-old girl, a go it er develo ped. Subc linical I ly pothyrnic.Jism was found, in addition rising titer of ant imicrosomal antibody and overt hypothyroidism after 6-week cessation of thyroxin tablet lead to the diagnosis of Hashimoto's thyroiditis. Antibodies directed to the thyroid may result in an autoimmune thyroiditis in...
متن کاملHematologic manifestation of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease. The most common hematologic finding is anemia, leukopenia, thrombocytopenia and secondary antiphospholipid syndrome with recurrent abortion and thrombosis. The autoimmune fibrosis of bone marrow is another manifestation of autoimmune disease especially SLE, that must be correctly differentiated from primary myelofibrosis.
متن کاملTreatment of systemic lupus erythematosus.
The treatment of systemic lupus erythematosus (SLE) is mainly based on a number of "traditional" drugs such as corticosteroids, antimalarials, azathioprine and cyclophosphamide. However, this scenario is rapidly changing due to the introduction of new compounds. Some of these new agents have been successfully used in other diseases, while others are being specifically designed to interfere with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis Care & Research
سال: 2002
ISSN: 0004-3591
DOI: 10.1002/art.10289